Paul Carvey to Humans
This is a "connection" page, showing publications Paul Carvey has written about Humans.
Connection Strength
0.195
-
The blood-brain barrier in neurodegenerative disease: a rhetorical perspective. J Neurochem. 2009 Oct; 111(2):291-314.
Score: 0.019
-
Neuroinflammation and peripheral immune infiltration in Parkinson's disease: an autoimmune hypothesis. Cell Transplant. 2008; 17(4):363-72.
Score: 0.017
-
Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant. 2006; 15(3):239-50.
Score: 0.014
-
Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease. Front Biosci. 2003 Sep 01; 8:s826-37.
Score: 0.012
-
Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp Neurol. 2001 Jun; 169(2):219-30.
Score: 0.011
-
Rapid approach to the quantitative determination of topiramate (2, 3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate) in human plasma by liquid-liquid extraction and flow-injection negative-ion electrospray mass spectrometry. Rapid Commun Mass Spectrom. 1999; 13(20):1980-4.
Score: 0.009
-
Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology. 1998 Feb; 50(2):515-7.
Score: 0.008
-
The stability of carbidopa in solution. Mov Disord. 1997 Jul; 12(4):608-10.
Score: 0.008
-
Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology. 1996 Dec; 47(6):1493-5.
Score: 0.008
-
Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology. 1996 Oct; 47(4):1037-42.
Score: 0.008
-
Cerebrospinal fluid from patients with Parkinson's disease alters the survival of dopamine neurons in mesencephalic culture. Exp Neurol. 1994 Mar; 126(1):15-24.
Score: 0.006
-
Alterations in striatal neurotrophic activity induced by dopaminergic drugs. Pharmacol Biochem Behav. 1993 Sep; 46(1):195-204.
Score: 0.006
-
Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures. Exp Neurol. 1993 Mar; 120(1):149-52.
Score: 0.006
-
Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy. J Neural Transm (Vienna). 2012 Jan; 119(1):59-71.
Score: 0.005
-
The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's disease. Neurology. 1991 May; 41(5 Suppl 2):53-8; discussion 59-60.
Score: 0.005
-
Disappearance of a putative DA-neuron antibody following adrenal medulla transplantation: relationship to a striatal-derived DA neuron trophic factor. Prog Brain Res. 1990; 82:693-7.
Score: 0.005
-
Evidence of angiogenic vessels in Alzheimer's disease. J Neural Transm (Vienna). 2009 May; 116(5):587-97.
Score: 0.005
-
An antibody in the CSF of Parkinson's disease patients disappears following adrenal medulla transplantation. Neurosci Lett. 1988 Nov 22; 94(1-2):192-7.
Score: 0.004
-
Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. Environ Health Perspect. 2009 Jan; 117(1):117-21.
Score: 0.004
-
Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant. 2007; 16(3):285-99.
Score: 0.004
-
Animal models of tardive dyskinesias. Clin Neuropharmacol. 1983 Jun; 6(2):129-35.
Score: 0.003
-
Animal models of tardive dyskinesia: their use in the search for new treatment methods. Mod Probl Pharmacopsychiatry. 1983; 21:5-20.
Score: 0.003
-
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
Score: 0.003
-
Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells. Exp Neurol. 2001 Aug; 170(2):317-25.
Score: 0.003
-
Analysis of 9-fluorenylmethyloxycarbonyl derivatives of catecholamines by high performance liquid chromatography, liquid chromatography/mass spectrometry and tandem mass spectrometry. Rapid Commun Mass Spectrom. 1999; 13(18):1869-77.
Score: 0.002
-
TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Exp Neurol. 1996 Dec; 142(2):313-22.
Score: 0.002
-
Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use. Mov Disord. 1996 Jan; 11(1):24-6.
Score: 0.002
-
Dopamine-responsive neurotrophic factor in schizophrenia. Schizophr Res. 1995 Dec; 18(1):83-4.
Score: 0.002
-
Blood levodopa levels and unified Parkinson's disease rating scale function: with and without exercise. Neurology. 1993 May; 43(5):1040-2.
Score: 0.002
-
Clinical improvement in parkinsonian patients undergoing adrenal to caudate transplantation is not reflected by chromogranin A or basic fibroblast growth factor in ventricular fluid. Exp Neurol. 1991 Mar; 111(3):276-81.
Score: 0.001
-
Investigations on auto-antibodies in Alzheimer's and Parkinson's diseases, using defined neuronal cultures. J Neural Transm Suppl. 1990; 29:195-206.
Score: 0.001
-
Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology. 1988 Jul; 38(7):1143-6.
Score: 0.001
-
Drug-induced myoclonus. Adv Neurol. 1986; 43:251-64.
Score: 0.001
-
The pathophysiology of tardive dyskinesia. J Clin Psychiatry. 1985 Apr; 46(4 Pt 2):38-41.
Score: 0.001
-
Neuroleptic-induced dopamine hyposensitivity. Life Sci. 1984 Apr 09; 34(15):1475-9.
Score: 0.001
-
Long-term suppression of central serotonergic activity by corticosteroids: a possible model of steroid-responsive myoclonic disorders. Neurology. 1982 Jul; 32(7):772-5.
Score: 0.001
-
Modification of central serotonergic and dopaminergic behaviors in the course of chronic corticosteroid administration. Eur J Pharmacol. 1982 Mar 12; 78(3):335-43.
Score: 0.001
-
Effect of chronic levodopa on haloperidol-induced behavioral supersensitivity in the guinea pig. Adv Neurol. 1982; 35:213-9.
Score: 0.001
-
The effect of chronic levodopa on haloperidol induced behavioral supersensitivity in the guinea pig. Life Sci. 1981 May 11; 28(19):2173-8.
Score: 0.001
-
Correlation between daily dosage of chlorpromazine and subsequent supersensitivity. Adv Biochem Psychopharmacol. 1980; 24:569-72.
Score: 0.001
-
Dopaminergic antagonism of L-5-hydroxytryptophan-induced myoclonic jumping behavior. Neurology. 1979 Dec; 29(12):1622-5.
Score: 0.001